Open Nav

ActoBio Therapeutics

  • Pieter Rottiers, ActoBio Therapeutics

trigger investors for 1:1

  • Date:Wednesday, October 17
  • Time:4:00 PM - 4:15 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ActoBio Therapeutics, Inc., a subsidiary of Intrexon Corporation (NYSE: XON) and innovative clinical stage biotechnology company, is pioneering a new class of therapeutic agent: ActoBiotics®. They are specifically designed and engineered to yield therapeutic agents for topical delivery, providing potentially disease-modifying treatments for immune-related and other diseases. Since ActoBiotics® are based on the well-characterized food-grade microorganism, Lactococcus lactis, this approach promises safer and more ecacious treatments than injectable agents. A broad portfolio of ActoBiotics® is being developed to treat a number of diseases, focusing primarily on disease areas with high unmet needs in immunotherapy, allergy and tolerance induction, such as Type 1 Diabetes.
  • Company
  • Company HQ City:Germantown
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development :AG013 in oral mucositis
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:The ActoBiotics technology provides a new class of therapeutic agent, a unique delivery platform precisely tailored for specific disease modification, with the potential for superior efficacy and safety via topical delivery directly to the relevant tissue. It combines the advantages of highly selective protein-based therapeutic agents with topical delivery by the well-characterized food bacterium Lactococcus lactis, to provide novel disease-modifying therapies. ActoBiotics have the potential to provide superior safety and efficacy via the sustained release of appropriate quantities of select therapeutic agents, while reducing the side-effects commonly attributed to systemic delivery and the corresponding peaks in concentration. ActoBio Therapeutics has shown that multiple therapeutic agents, such as proteins, peptides and antibodies, can be incorporated into a single approach, enabling the simultaneous targeting of multiple pathways in one disease
  • Total Amount Raised to Date, In All Rounds:wholly owned subsidiary
Pieter Rottiers
ActoBio Therapeutics